[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aneurysm-ruptured\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aneurysm-ruptured":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100553501","shunt-dependency-after-asah---role-of-early-hyperglycaemia-in-csf-and-blood-100553501",false,"NCT06486909","Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood","Shunt-dependency After Aneurysmal Subarachnoid Haemorrhage - the Role of Early Hyperglycaemia in Cerebro-spinal Fluid and Blood","HCP-Glc","Inclusion Criteria:\n\n* 18 years old and older\n* Hospital admission due to an aneurysmal subarachnoid haemorrhage (radiological confirmation needed)\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Non-aneurysmal subarachnoid haemorrhage (eg. trauma, perimesencephalic subarachnoid haemorrhage, mycotic or flow-associated aneurysms)\n* Previous enrolment into the current study","ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","OBSERVATIONAL","The goal of this study is to confirm the association of early increased glucose levels in cerebro-spinal fluid (CSF) and ventriculo-peritoneal-shunt (VPS)-dependency also evaluating the influence of blood glucose on VPS dependency in patients suffering from an aneurysmal subarachnoid haemorrhage (aSAH). The main questions we aim to answer are:\n\n* Is there an association of glucose levels on VPS dependency in patients requiring extra-ventricular-drain (EVD) placement for aSAH?\n* In addition, if there is, what is the influence the course of glucose levels has on VPS dependency?\n\nGlucose levels in CSF and serum will be measured on admission, or in case of CSF, upon EVD placement. Glucose in CSF will then be measured every day until EVD removal together with serum glucose. Follow-up will be conducted in person after 3 and 6 months.",[25,26,27],"Aneurysm, Ruptured","Hyperglycemia","Hydrocephalus",[29,30,31,32,33],"aneurysmal subarachnoid haemorrhage","hyperglycaemia","hydrocephalus","ventriculo-peritoneal shunt","extra-ventricular drain","RECRUITING","2026-03-17",{"date":37,"type":38},"2026-03-18","ACTUAL",{"date":40,"type":38},"2024-03-26",{"date":42,"type":21},"2028-09",{"name":44,"class":45},"Isabel Hostettler","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100596815","the-risk-factors-related-to-rupture-flow-related-aneurysms-in-posterior-avm-100596815","NCT07050381","The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM","Risk Factors Related to Rupture Flow-related Aneurysms in Posterior Arteriovenious Malformation: A Muti-center Observentional Research.","pAVM-rFA","Inclusion Criteria:\n\n1. pAVM with flow-related aneurysms were identified by DSA, and subarachnoid hemorrhage was confirmed by CT\n2. No history of stroke, Marfan syndrome, polycystic kidney disease\n\nExclusion Criteria:\n\n1. pAVM without flow-related aneurysms\n2. Absence of clinical data",{"count":55,"type":21},200,"AVMs have been reported to rupture at a formidable annual rate of 2% to 3% at natural progression, often resulting in longterm neurological deficits and poor functional outcomes.The reported risk of hemorrhagic presentation in patients with AVMs is 41% to 65%. While many studies suggest a correlation between higher hemorrhage risk and the concurrent presence of AVM and aneurysms, few authors have focused specifically on flow-related aneurysms alone. In many instances, the source of rupture is also unclear. Meta-analysis from 2016 suggested that 49.2% of hemorrhages were secondary to aneurysm rupture, 45% from AVM rupture, and 5.7% were undetermined.In a study of 302 patients, of which 52.6% had a hemorrhagic presentation, demonstrated a significant increase in rate of hemorrhage in those with flow-related aneurysms. Thus, it is necessary to figure out risk factors related to ruptured flow-related aneurysms in pAVM.",[58,25,59,60],"Arteriovenous Malformation of Central Nervous System","Aneurysmatic Subarachnoid Haemorrhage","Aneurysm Cerebral",[62,63,64,65],"arteriovenous malformation","flow-related aneurysm","ruptured aneurysm","subarachnoid hemorrhage","2025-06-25",{"date":68,"type":38},"2025-07-03",{"date":70,"type":38},"2025-06-13",{"date":72,"type":21},"2026-12-31",{"name":74,"class":45},"The First Affiliated Hospital with Nanjing Medical University",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":85,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100506922","sealme-saccular-endovascular-aneurysm-lattice-system-multicenter-enrollment-global-registry-100506922","NCT05880680","SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry","SEAL™ME","Inclusion Criteria:\n\n1. 18 to 80 years of age at the time of screening.\n2. Unruptured aneurysm requiring endovascular treatment suitable for SEAL device and meet the AHA guidelines for management of unruptured aneurysm.5 If there is evidence of an additional aneurysm requiring treatment, the secondary aneurysm must also be treatable using a SEAL™ System Device, either during a single procedure or consecutive procedures.\n\n   No additional preplanned implanted devices are permissible except for as medically required for patient safety during the procedure.\n3. Ruptured aneurysm\n\n   1. Ruptured aneurysms may be included according to the following criteria: The subject is neurologically stable with no seizure at the onset of the SAH, not requiring EVD placement prior to inclusion.\n   2. Hunt and Hess scale of 3 or less at the time of treatment.\n   3. Modified Disability Scale (mRS) of ≤2 prior to presentation or aneurysm rupture.\n   4. Meet the AHA guidelines for management of ruptured aneurysm.6\n4. The index intracranial aneurysm (IA) to be treated must include the following features:\n\n   1. Aneurysm features suitable for endovascular treatment with an intrasaccular device per the treating interventionist.\n   2. Saccular morphology.\n   3. Located at a bifurcation, terminus, or sidewall in the anterior or posterior circulation.\n   4. 2.5 mm-20 mm in dome diameter.\n   5. Wide-neck aneurysm with neck size ≥ 4mm or Dome-to-Neck (DN) ratio \\\u003C 2.\n5. Aneurysm treatment does not require the preplanned use of any additional implanted devices.\n6. Subject is able to maintain compliance with all aspects of screening, evaluation, treatment, and post-procedure follow-up schedule.\n7. Baseline pre-procedure mRS of 0-2 for unruptured aneurysm and 0-2 prior to the SAH for the ruptured aneurysms.\n8. Ability to obtain written informed consent from subject or legally authorized representative in SAH subjects prior to the initiation of any study procedures.\n\nExclusion Criteria:\n\n1. Aneurysm features unsuitable for endovascular treatment with an intrasaccular device such as fusiform, dissecting pseudo aneurysm, or mycotic aneurysm.\n2. Aneurysms smaller than 2.5 mm and larger than 20 mm in dome width.\n3. Inability to access target aneurysm with microcatheter due to intracranial atherosclerosis, proximal or intracranial vessel tortuosity or poor aneurysm angle take-off.\n4. Patients with two 360 degrees loops in the carotid or vertebral arteries.\n5. Presence of vascular disease or other vascular abnormality that could prohibit access to index aneurysm such carotid stenosis or diminished caliber of the target artery.\n6. Clinical, angiographic, or CT evidence of CNS arterial vasculitis, Moyamoya disease, intracranial tumor (except small meningioma), or any other intracranial vascular malformations.\n7. Patients with high risk for recurrent ischemic stroke due to previous history of ischemic stroke symptoms such as transient ischemic attacks (TIAs), minor, or major strokes within the past 60 days. Other stroke risk factors such as intracranial stenosis or atrial fibrillation.\n8. Patients with hemodynamic or medical compromise due to medical comorbidities such as severe unstable congestive heart failure (ejection fraction \\\u003C30%) or severe COPD requiring home oxygen.\n9. Modified Rankin Scale (mRS) score of \\> 2 prior to presentation.\n10. Target index aneurysm that has been previously treated and contains devices, implants, or coils that could interfere with correct SEAL™ device placement.\n11. Subject is pregnant or a lactating female (For females of child-bearing potential, a positive pregnancy test within 7 days of the day of procedure or refusal to use a medically accepted method of birth control for the duration of the study.\n12. Currently on anticoagulation therapy or has a known blood dyscrasia, coagulopathy, or hemoglobinopathy.\n13. Currently enrolled in another investigational study or post-market study that could affect the safety and efficacy of aneurysm treatment or interfere with the study follow-up schedule.\n14. Presence of an acute life-threatening illness requiring treatment.\n15. Life expectancy of \\\u003C1 year.\n16. Subject has an uncontrolled co-morbid medical condition, that would adversely affect participation in the study.\n17. Patient with chronic kidney disease (and not on dialysis) with creatinine \\> 2.0.\n18. Subject is a prisoner or member of other vulnerable population.\n19. Subject that is in the opinion of the treating interventionalist is not suitable for the study.\n\n    * Sensitivity to nickel is not specifically excluded, Galaxy Therapeutics, Inc (GTI) performed ASTM F2129 testing recommended by the FDA in its 2015 and 2019 guiding documents. GTI results from the testing indicated that SEALTM meets the acceptance criteria that there is a high probability that the margin of safety against pitting (Eb-Er) is 200mV or higher, therefore, with high confidence, no further testing is required. The IFU contains the following precaution: \"For patients with known hypersensitivity or allergic reaction to the implant components such as titanium or to nickel, use of the SEALTM System may lead to allergic reaction and user should counsel the patient on the device components\".","80 Years",{"count":55,"type":21},"5 Years","Prospective, international, single-arm, multicenter, registry study. Patients presenting with evidence of Wide Neck unruptured or ruptured intracranial aneurysm (≤ 20 mm in widest diameter) requiring treatment will be enrolled into the study and treated using the SEAL™ System.",[88,25],"Aneurysm","2025-04-01",{"date":91,"type":38},"2025-04-04",{"date":93,"type":38},"2023-10-09",{"date":95,"type":21},"2030-06-15",{"name":97,"class":98},"Galaxy Therapeutics INC","INDUSTRY",4]